Search for a trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat
Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis
(DT/AF).

Primary:To determine the efficacy (as defined by progression-free survival [PFS]) of nirogacestat in adult participants with progressing DT/AF.Secondary:To evaluate the safety and tolerability of nirogacestat in adult participants with progressing…

A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder Cancer: the CRIMI study.

This study has been transitioned to CTIS with ID 2023-509460-19-00 check the CTIS register for the current data. *In the phase Ib study: to assess the feasibility and safety of the addition of nivolumab and/or ipilimumab to MMC/capecitabine…

Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.

Primary objective* To study the antitumor activity and safety of crizotinib across predefined tumor types in patients whose tumors are harboring specific alterations in ALK and/or METSecondary objectives* To study the specificity of the kinase…

Microsampling for therapeutic drug monitoring of imatinib, dasatinib, nilotinib, gilteritinib, midostaurin, and venetoclax

The primary objective is to perform a clinical validation of dried blood spot microsampling of imatinib, dasatinib, nilotinib, gilteritinib, midostaurin, and venetoclax. The secondary objective is to test the feasibility of home monitoring (…

Feasibility of primer shot radiotherapy for non-small cell lung cancer (PRIMER)

To determine the safety and feasibility of primer shot fractionation for NSCLC.

Immune sparing Radiotherapy strategies In head and neck Squamous cell carcinoma (IRIS)

To study the immune effects of novel radiotherapy schedules by longitudinal immune profiling. There will be a specific focus on actionable immune targets and their temporal patterns that can be tested in future immune-radiotherapy combination trials…

A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin

This study has been transitioned to CTIS with ID 2023-508528-36-00 check the CTIS register for the current data. The purpose of this study is to demonstrate improvement in Disease-Free Survival (DFS) with xevinapant compared to placebo when added to…

Setup and intra-fractional motion measurements using surface scanning in head and neck cancer patients positioned with an individual head base

The aim of the study is to investigate the accuracy of initial positioning, stability during treatment (intrafraction motion), and the number of interventions (repositioning) for radiotherapy treatments of head and neck cancer patients, positioned…

A Randomized Controlled Trial on Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy

To improve survival after recurrence in patients with isolated local PDAC recurrence using local ablative treatment with SBRT inaddition to standard of care.

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy

The primary objective is to compare the efficacy of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival (PFS) in subjects with newly diagnosed…

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma

* Safety Run inTo determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for the randomized part (part 3)* Biomarker cohortTo evaluate changes in the immune microenvironment and biomarker modulations upon treatment…

Assessing optimal treatment settings for the ablation of locally advanced pancreatic cancer with CT-guided percutaneous irreversible electroporation: a randomized feasibility study.

The objective of this study is to compare two IRE protocols for the treatment of LAPC that are currently being used in clinical treatment, to allow for the determination (based on survival and co-morbidity) of the optimal treatment protocol for IRE…

A phase II, open label, multi-center study of 89Zr-DF-Crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumours

This study has been transitioned to CTIS with ID 2024-515885-15-00 check the CTIS register for the current data. Main objectives:• To evaluate whole body distribution of 89Zr-Df-crefmirlimab in cancer patients prior to and during treatment with an…

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

This study has been transitioned to CTIS with ID 2024-514266-39-00 check the CTIS register for the current data. Phase 1 Primary Objective(s):-to evaluate the overall safety and tolerability of NVL-655-to determine the RP2D and, if applicable, the…

Utrecht Breathing Regulation Effectiveness for Abdominal and THoracic External-beam Radiotherapy (U-BREATHER)

To assess the feasibility of participants positioned in an MRI scanner to regulate their breathing based on biofeedback

A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RUNIMOTAMAB ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUAMB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS

This study has been transitioned to CTIS with ID 2023-504491-15-00 check the CTIS register for the current data. • To evaluate the safety and tolerability of Runimotamab when administered as a single agent (Phase Ia) and in combination with…

The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial

This study has been transitioned to CTIS with ID 2024-519750-36-00 check the CTIS register for the current data. The primary aim of this study is to determine the feasibility of using intraoperative fluorescence-imaging (FLI) to identify laryngeal…

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors

This study has been transitioned to CTIS with ID 2023-509605-77-00 check the CTIS register for the current data. Primary objectives (Dose-escalation Phase):• To evaluate the safety and tolerability, describe the dose-limiting toxicities (DLTs), to…

Magnetic resonance imaging-guided focal laser ablation of prostate cancer

Primary objectiveThe primary objective for this phase IIa study is to investigate the feasibility, usability and safety of CLS MR-guided FLA in the treatment of prostate cancer.Secondary objectiveTo assess tumor response and functional outcomes

Expression of chemokine receptors upon doxorubicin treatment in breast cancer and sarcoma patients.

To get a better understanding of the kinetics of the expression of CXCR1, CXCR2 and the CXCR1/2 ligands (including IL-8), blood samples of patients with breast cancer or sarcoma will be collected at different timepoints. We expect that with these…